このエントリーをはてなブックマークに追加
ID 53675
JaLCDOI
FullText URL
Author
Sugiu, Kumi
Kelly, Catherine M.
Watanabe, Naoki
Itoh, Mitsuya
Ohtani, Shoichiro
Higaki, Kenji
Imada, Takako
Yuasa, Takeshi
Omori, Masako
Sonobe, Hiroshi
Abstract
Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
Keywords
breast cancer
neoadjuvant chemotherapy
concurrent hormone therapy
estrogen receptor positive
tumor response
Amo Type
Original Article
Published Date
2015-10
Publication Title
Acta Medica Okayama
Volume
volume69
Issue
issue5
Publisher
Okayama University Medical School
Start Page
291
End Page
299
ISSN
0386-300X
NCID
AA00508441
Content Type
Journal Article
language
英語
Copyright Holders
CopyrightⒸ 2015 by Okayama University Medical School
File Version
publisher
Refereed
True
PubMed ID
Web of Sience KeyUT